Steigerwald Gordon & Koch’s Ligand Pharmaceuticals LGND Stock Holding History

Steigerwald Gordon & Koch’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$313K	Hold	1,566	–	–	0.03%	107
2025 Q4	$296K	Hold	1,566	–	–	0.03%	112
2025 Q3	$277K	Buy	+1,566	New	+$233K	0.03%	114
2022 Q1	–	Sell	-2,510	Closed	-$242K	–	120
2021 Q4	$242K	Hold	2,510	–	–	0.04%	104
2021 Q3	$218K	Hold	2,510	–	–	0.04%	109
2021 Q2	$205K	Hold	2,510	–	–	0.03%	112
2021 Q1	$239K	Buy	+2,510	New	+$237K	0.04%	93
2019 Q1	–	Sell	-2,510	Closed	-$213K	–	85
2018 Q4	$213K	Hold	2,510	–	–	0.06%	80
2018 Q3	$430K	Hold	2,510	–	–	0.11%	59
2018 Q2	$324K	Buy	+2,510	New	+$280K	0.09%	68
2018 Q1	–	Sell	-2,510	Closed	-$214K	–	85
2017 Q4	$214K	Buy	+2,510	New	+$218K	0.06%	79
2017 Q3	–	Sell	-2,671	Closed	-$202K	–	90
2017 Q2	$202K	Buy	+2,671	New	+$187K	0.06%	83
2016 Q4	–	Sell	-3,203	Closed	-$204K	–	88
2016 Q3	$204K	Hold	3,203	–	–	0.07%	67
2016 Q2	$238K	Hold	3,203	–	–	0.09%	59
2016 Q1	$214K	Hold	3,203	–	–	0.08%	58
2015 Q4	$217K	Buy	+3,203	New	+$198K	0.09%	54
2015 Q2	–	Sell	-16,880	Closed	-$328K	–	52
2015 Q1	$328K	Buy	+16,880	New	+$647K	0.15%	44

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Steigerwald Gordon & Koch's LGND Position: Q1 2026 in Review

Steigerwald Gordon & Koch held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 1,566 shares worth $313K. The position accounts for 0.03% of the portfolio, ranked #107.

Steigerwald Gordon & Koch first reported a position in LGND in Q1 2015 and has held it in 17 quarters since. The position peaked at $430K in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

Steigerwald Gordon & Koch held 1,566 shares of Ligand Pharmaceuticals worth $313K as of Q1 2026.
Steigerwald Gordon & Koch left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
Ligand Pharmaceuticals made up 0.03% of Steigerwald Gordon & Koch's portfolio in Q1 2026, its #107 holding.
Steigerwald Gordon & Koch first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 17 quarters since.
Steigerwald Gordon & Koch's Ligand Pharmaceuticals position peaked at $430K in Q3 2018.
357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q1 2026, filed 28 Apr 2026.